Jason Wittes
Stock Analyst at Roth Capital
(2.63)
# 1,812
Out of 5,182 analysts
58
Total ratings
48.08%
Success rate
3.82%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $8.14 | +391.40% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $345.88 | +31.84% | 11 | May 2, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $2.42 | +561.16% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $12.72 | +72.96% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $93.56 | -23.04% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $4.40 | +150.00% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $94.94 | +21.13% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $5.26 | +109.13% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.40 | +614.29% | 1 | Jun 26, 2024 | |
| LMAT LeMaitre Vascular | Reinstates: Buy | $100 | $117.39 | -14.81% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.03 | +146.31% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.40 | +2,147.75% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $25.10 | +198.80% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.52 | +90.97% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $96.52 | +24.33% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $178.39 | +15.48% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $197.98 | -26.76% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7.5 | $14.97 | -49.90% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $11.30 | +1,669.91% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $34.56 | -24.77% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $8.14
Upside: +391.40%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $345.88
Upside: +31.84%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $2.42
Upside: +561.16%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $12.72
Upside: +72.96%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $93.56
Upside: -23.04%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $4.40
Upside: +150.00%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $94.94
Upside: +21.13%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $5.26
Upside: +109.13%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
LeMaitre Vascular
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $117.39
Upside: -14.81%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $2.03
Upside: +146.31%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.40
Upside: +2,147.75%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $25.10
Upside: +198.80%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $11.52
Upside: +90.97%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $96.52
Upside: +24.33%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $178.39
Upside: +15.48%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $197.98
Upside: -26.76%
Mar 3, 2022
Initiates: Buy
Price Target: $7.5
Current: $14.97
Upside: -49.90%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $11.30
Upside: +1,669.91%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $34.56
Upside: -24.77%